Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 2/2013

01-02-2013 | Brief Research Article

Methylation in the p53 promoter in epithelial ovarian cancer

Authors: Marcela Chmelarova, E. Krepinska, J. Spacek, J. Laco, M. Beranek, V. Palicka

Published in: Clinical and Translational Oncology | Issue 2/2013

Login to get access

Abstract

Objective

Ovarian cancer is a leading cause of death from gynecologic tumors, however, the molecular and especially epigenetic events underlying this transformation are poorly understood. Promoter methylation status of tumor suppressor genes may be associated with transcriptional silencing and tumor progression. It has been shown that methylation of CpG dinucleotides located in the promoter region of p53 is associated with low expression levels of this gene. The aim of this study was to investigate promoter methylation of p53 gene in ovarian cancer by comparison with normal ovarian tissue.

Methods

To search for promoter methylation of p53 gene we used methylation-specific PCR (MSP) to compare the methylation status of 66 tissue samples of ovarian cancer with 37 control samples.

Results

In our study methylation specific PCR revealed p53 promoter methylation in 34 of 66 (51.5 %) of specimens with ovarian cancer.

Conclusion

These results indicate that methylation in p53 promoter region may play an important role in carcinogenesis of ovarian cancer and could potentially be used in screening of ovarian cancer, and may have implications for future chemotherapy based on epigenetic changes.
Literature
1.
Beth YK (2009) Patients at high risk for ovarian cancer should undergo routine screening. Clin Ovarian Cancer 2:83–89CrossRef
2.
3.
Chan KY, Ozçelik H, Cheung AN, Ngan HY, Khoo US (2002) Epigenetic factors controlling the BRCA1 and BRCA2 genes in sporadic ovarian cancer. Cancer Res 62(14):4151–4156PubMed
4.
Yoon JH, Dammann R, Pfeifer GP (2001) Hypermethylation of the CpG island of the RASSF1A gene in ovarian and renal cell carcinomas. Int J Cancer 94(2):212–217PubMedCrossRef
5.
Gras E, Catasus L, Argüelles R, Moreno-Bueno G, Palacios J, Gamallo C, Matias-Guiu X, Prat J (2001) Microsatellite instability, MLH-1 promoter hypermethylation, and frameshift mutations at coding mononucleotide repeat microsatellites in ovarian tumors. Cancer 92(11):2829–2836PubMedCrossRef
6.
Feng W, Marquez RT, Lu Z, Liu J, Lu KH, Issa JP, Fishman DM, Yu Y, Bast RC Jr (2008) Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation. Cancer 112(7):1489–1502PubMedCrossRef
7.
Mei FC, Young TW, Liu J, Cheng X (2006) RAS-mediated epigenetic inactivation of OPCML in oncogenic transformation of human ovarian surface epithelial cells. FASEB J 20(3):497–499PubMed
8.
9.
Tuck SP, Crawford L (1989) Characterization of the human p53 gene promoter. Mol Cell Biol 9(5):2163–2172PubMed
10.
Marks JR, Davidoff AM, Kerns BJ et al (1991) Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res 51(11):2979–2984PubMed
11.
Kang JH, Kim SJ, Noh DY, Park IA, Choe KJ, Yoo OJ, Kang HS (2001) Methylation in the p53 promoter is a supplementary route to breast carcinogenesis: correlation between CpG methylation in the p53 promoter and the mutation of the p53 gene in the progression from ductal carcinoma in situ to invasive ductal carcinoma. Lab Invest 81(4):573–579PubMedCrossRef
12.
Amatya VJ, Naumann U, Weller M, Ohgaki H (2005) TP53 promoter methylation in human gliomas. Acta Neuropathol 110(2):178–184PubMedCrossRef
13.
Agirre X, Vizmanos JL, Calasanz MJ, García-Delgado M, Larráyoz MJ, Novo FJ (2003) Methylation of CpG dinucleotides and/or CCWGG motifs at the promoter of TP53 correlates with decreased gene expression in a subset of acute lymphoblastic leukemia patients. Oncogene 22(7):1070–1072PubMedCrossRef
14.
Pogribny IP, James SJ (2002) Reduction of p53 gene expression in human primary hepatocellular carcinoma is associated with promoter region methylation without coding region mutation. Cancer Lett 176(2):169–174PubMedCrossRef
15.
Tavassoli FA, Devilee P (eds) (2003) World Health Organization classification of tumors: pathology and genetics of tumors of the breast and female genital organs. IARC Press, Lyon, pp 113–202
16.
Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB (1996) Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93(18):9821–9826PubMedCrossRef
Metadata
Title
Methylation in the p53 promoter in epithelial ovarian cancer
Authors
Marcela Chmelarova
E. Krepinska
J. Spacek
J. Laco
M. Beranek
V. Palicka
Publication date
01-02-2013
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 2/2013
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-012-0894-z

Other articles of this Issue 2/2013

Clinical and Translational Oncology 2/2013 Go to the issue

Erratum

Erratum to: Ultrasound-assisted endocavitary HDR-Ir192 brachytherapy for unresectable locally advanced uterine cervix carcinoma: retrospective analysis focusing the efficacy and tolerability

Research Article

Human adipose tissue from normal and tumoral breast regulates the behavior of mammary epithelial cells

Research Article

Sorafenib for non-selected patient population with advanced hepatocellular carcinoma: efficacy and safety data according to liver function

Research Article

Multicenter validation of two nomograms to predict non-sentinel node involvement in breast cancer

Research Article

Quantitative analysis of EZH2 expression and its correlations with lung cancer patients’ clinical pathological characteristics

Research Article

Daily schedule for high-dose-rate brachytherapy in postoperative treatment of endometrial carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits